ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

In vitro susceptibility of non-candidal yeasts to systemically active antifungal agents determined by CLSI M27 broth microdilution methods

In vitro susceptibility of non-candidal yeasts to systemically active antifungal agents determined by CLSI M27 broth microdilution methods
Organism Antifungal agent Number tested MIC, mcg/mL
Range 50 percent* 90 percent*
Cryptococcus neoformans Amphotericin B 661 0.03 to 32 0.5 1
Flucytosine 1614 0.06 to 128 4 8
Fluconazole 1615 0.007 to 64 4 8
Isavuconazole 438 <0.008 to 0.5  0.03 0.06
Itraconazole 1615 0.007 to 64 0.25 4
Posaconazole 1437 0.007 to 2 0.12 0.25
Voriconazole 1608 0.007 to 2 0.06 0.12
Trichosporon asahii Amphotericin B 43 1 to 8 4 4
Fluconazole 43 0.25 to 16 2 8
Itraconazole 43 0.06 to 4 0.5 1
Posaconazole 24 0.06 to >16 0.12 N/A
Voriconazole 10 0.25 to 2 0.5 2
Other Trichosporon spp Amphotericin B 15 0.06 to 1 0.25 N/A
Fluconazole 15 0.5 to 4 2 N/A
Itraconazole 15 0.03 to 0.5 0.12 N/A
Posaconazole 15 0.03 to 0.5 0.12 N/A
Voriconazole 15 0.03 to 0.25 0.06 N/A
Rhodotorula spp Amphotericin B 64 0.5 to 2 1 1
Flucytosine 64 0.06 to 0.5 0.12 0.25
Fluconazole 64 32 to >64 >64 >64
Itraconazole 64 0.5 to 16 2 16
Posaconazole 64 0.5 to 16 2 4
Voriconazole 64 0.25 to 16 2 4
Saccharomyces cerevisiae Amphotericin B 74 0.12 to 2 1 1
Flucytosine 74 0.25 to 32 0.25 0.25
Fluconazole 74 0.12 to 16 2 8
Itraconazole 74 0.015 to 1 0.5 1
Posaconazole 22 0.12 to 1 0.5 0.5
Voriconazole 17 0.007 to 0.5 0.06 0.12
Saprochaetae capitata Amphotericin B 23 0.06 to 0.25 0.12 0.12
Flucytosine 23 0.12 to 16 0.12 4
Fluconazole 23 1 to 32 8 8
Itraconazole 23 0.3 to 0.5 0.12 0.25
Posaconazole 25 N/A 0.12 0.25
Voriconazole 23 0.03 to 0.5 0.25 0.25
CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.
* MIC encompassing 50 percent and 90 percent of isolates tested, respectively.
¶ Amphotericin B MICs determined by Etest.
  1. Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929.
  2. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.
  3. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163.
  4. Arikan S, Hascelik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002; 43:107.
  5. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144.
  6. Serena C, Marine M, Pastor FJ, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48:2724.
  7. Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39.
  8. Diekema DJ, Petroelje B, Hollis RJ, Pfaller MA, Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005; 43:476.
  9. Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031.
  10. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233.
  11. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole, and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24.
  12. Pfaller MA, Diekema DJ, Merz WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Reports 2007; 1:53.
  13. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2015; 59:666.
Graphic 71985 Version 6.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟